Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 18/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.74 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.74 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.71 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.71 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13384982 | 1.00 | ADORA1 (0.74) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 | |
| SCHEMBL472511 | 1.00 | ADORA1 (0.74) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 | |
| Acetone SCHEMBL472504 | 0.96 | ADORA1 (0.71) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 | |
| SCHEMBL472664 | 0.91 | ADORA1 (0.72) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 | |
| SCHEMBL472547 | 0.91 | ADORA1 (0.70) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 | |
| SCHEMBL472548 | 0.91 | ADORA1 (0.72) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 | |
| SCHEMBL472667 | 0.91 | ADORA1 (0.72) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 | |
| SCHEMBL472608 | 0.90 | ADORA3 (0.73) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL472605 | 0.89 | ADORA1 (0.75) | ADORA1ADORA3ADORA2AADORA2BSLC28A1 | |
| SCHEMBL472561 | 0.89 | ADORA3 (0.65) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013049725-A2 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2013-04-04 | — | — | WO | claimed |
| US-20140241990-A1 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013049725-A2 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140241990-A1 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | ADORA2A, ADORA1, ADORA3 | ADORA1 2/4885ADORA3 3/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.